• Structure Therapeutics announced that Phase 2b ACCESS trial results for its oral GLP-1 receptor agonist aleniglipron in people with overweight or obesity were published in Nature Medicine and presented at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant efficacy across three maintenance doses and a safety profile consistent with the GLP-1 class.
• The interim open-label extension data, indicating durable weight loss beyond 36 weeks and improved gastrointestinal tolerability from a lower 2.5 mg starting dose, underpin the company’s plan to advance aleniglipron into a Phase 3 obesity program expected to start in the third quarter of 2026.
• With these Phase 2b results clarifying aleniglipron’s efficacy and tolerability profile, we’ll examine how this publication reshapes Structure Therapeutics’ investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

What Is Structure Therapeutics' Investment Narrative?

To own Structure Therapeutics, you need to believe that aleniglipron can carve out a meaningful role in the highly competitive obesity market and eventually convert its zero‑revenue, loss‑making profile into a commercial business. The Nature Medicine publication and ADA data help de‑risk the near‑term efficacy and tolerability story and should support the planned Phase 3 launch in the second half of 2026, which remains the key catalyst. At the same time, the mixed share price performance and H.C. Wainwright’s reduced target highlight that competitive pressure in GLP‑1s is front of mind, so this news may not fully offset concerns about differentiation and long development timelines. With cash burn still high and profitability not expected in the medium term, execution and funding remain central risks, even with stronger clinical validation.

However, the funding runway and future dilution risk are things investors should be watching closely. Our comprehensive valuation report raises the possibility that Structure Therapeutics is priced higher than what may be justified by its financials.

Exploring Other Perspectives

Three fair value views from the Simply Wall St Community span US$12 to US$120 per share, underscoring sharply different expectations for Structure’s upside as the aleniglipron Phase 3 program and funding needs come into focus.

Explore 3 other fair value estimates on Structure Therapeutics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Structure Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Structure Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Structure Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 43 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.